C1 inhibitor in sepsis and clinical outcome.
Geriatric Section Finnsnes, Department of Medicine, University Hospital North Norway, Tromsoe, Norway. Electronic address: harald.eugen.helling@unn.no.
Harald
H
Helling
Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University Hospital, Homburg, Germany.
Gerhard
G
Pindur
Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University Hospital, Homburg, Germany.
Bernhard
B
Stephan
D000328:Adult; D000368:Aged; D003167:Complement Activation; D003174:Complement C1 Inactivator Proteins / Q000008:administration & dosage / Q000502:physiology; D050718:Complement C1 Inhibitor Protein / Q000032:analysis*; D015853:Cysteine Proteinase Inhibitors / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D018805:Sepsis / Q000097:blood* / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D015853:Cysteine Proteinase Inhibitors